By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Investors usually focus on stocks that already have stellar dividend yields, but your portfolio could also benefit from ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy ® (semaglutide), which includes ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 million Danish ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

RoC Skincare® today announces its expanded commitment to empowered aging and supporting the long-term health and vitality of skin. Offering new research about aging perceptions, expert-backed ...

The Trump administration announced it will not finalize a rule proposed by the Biden administration that would have allowed ...

Article originally published by. FE fundinfo is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All ...

Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as its legal advisor. Evercore acted as the exclusive financial advisor ...

South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state ...